Metabolic Disease Models
Metabolic diseases, including diabetes, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and cardio-renal-metabolic (CKM) syndrome, affect over one billion individuals worldwide. As these conditions evolve into multi-organ systemic disorders, a significant translational gap remains between preclinical efficacy and clinical outcomes.
Creative Bioarray's models for metabolic diseases are specifically created to capture the advanced physiological aspects of the human versions. We focus on insulin resistance, systemic inflammation, and injury to key organs affected by metabolic dysfunction. Our preclinical metabolic disease services span from in vivo modeling, to multi-tiered analytics to help drive your drug discovery and translational research programs.
Our Model Portfolio
We categorize our models to align with specific therapeutic focus areas:
Liver & Lipid Disorders
Metabolic dysfunction-Associated Steatohepatitis (MASH) Model
Dyslipidemia Model
Obesity & Metabolic Syndrome
Metabolic Assays & Services
We provide integrated metabolic phenotyping services to generate actionable insights across efficacy, mechanism, and safety:
Metabolic Phenotyping
Energy expenditure
Respiratory exchange ratio (RER)
Physical activity
Body composition (fat/lean mass)
Glucose & Insulin Homeostasis
Glucose tolerance test (GTT)
Insulin tolerance test (ITT)
Clinical Biochemistry
Lipid profiles (TC, TG, HDL/LDL)
Liver enzymes (ALT/AST)
Metabolic hormones (insulin, leptin, adiponectin, glucagon)
Histopathology & Imaging
NAFLD Activity Score (NAS)
Fibrosis quantification (Sirius Red/Masson)
Lipid droplet staining (Oil Red O)
Pancreatic islet morphometry
Molecular Biomarkers
Pro-inflammatory cytokines (TNF-α, IL-6, MCP-1)
Targeted gene/protein expression analysis
Why Partner with Creative Bioarray?
Bridging the Translational Gap
Our multi-hit and diet-induced models capture complex disease features, including insulin resistance, systemic inflammation, and multi-organ involvement.
Validated Reference Benchmarks
Models are validated using clinically relevant reference compounds such as semaglutide, metformin, and SGLT2 inhibitors to ensure reproducibility and predictive performance.
Integrated Analytical Platform
From in vivo pharmacology to multi-omics biomarker analysis, we provide a one-stop solution for metabolic disease research.
Expert Scientific Support
Need help picking the right strain, diet or timeline for your study? Our metabolic experts are here to help you design a study tailored to your drug's Mechanism of Action (MoA).
FAQ
How do I choose the right metabolic disease model for my study?
The decision should be based on your drug's MoA and intended indication. Common customizations include:
- Adjusting dietary composition (e.g., standard high-fat diet vs. Western diet)
- Combining multiple disease drivers (e.g., obesity with fibrosis)
- Selecting disease-relevant biomarker panels aligned with your drug's MoA
Our scientists can help you design the most suitable metabolic disease model strategy.
Can the models and study design be customized for specific drug programs?
Absolutely! Customization is built into our service. Given that metabolic diseases usually stem from a mix of issues, we frequently tailor our models to match the specific research needs. Common customizations include adjusting dietary components (standard high fat diet vs western diet) (engineered to combine multiple disease drivers (obesity and fibrosis, etc.) or selecting disease-specific biomarker panels that are targeted to your drug's MoA. These personalized metabolic models allow for a more precise evaluation of your drug's impact and its underlying processes.
Do you provide end-to-end metabolic disease research services?
Yes, we offer fully integrated preclinical metabolic disease services that cover the entire study workflow. This includes animal model establishment, in vivo pharmacology studies, metabolic phenotyping, histopathology, and molecular biomarker analysis, as well as data interpretation and reporting. By consolidating these capabilities into a single platform, we help ensure data consistency, streamline project management, and accelerate your drug development timeline.
Accelerate Your Metabolic Drug Discovery
Whether you are developing therapies for diabetes, obesity, MASH, or CKM syndrome, our preclinical metabolic disease models can help you generate clinically relevant data to support translational and preclinical development.